Frontiers in Immunology (Jan 2025)
Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels
- Thomas M. Snyder,
- Rachel M. Gittelman,
- Mark Klinger,
- Damon H. May,
- Edward J. Osborne,
- Ruth Taniguchi,
- H. Jabran Zahid,
- Ian M. Kaplan,
- Jennifer N. Dines,
- Matthew T. Noakes,
- Ravi Pandya,
- Xiaoyu Chen,
- Summer Elasady,
- Emily Svejnoha,
- Peter Ebert,
- Mitchell W. Pesesky,
- Patricia De Almeida,
- Hope O’Donnell,
- Quinn DeGottardi,
- Gladys Keitany,
- Jennifer Lu,
- Allen Vong,
- Rebecca Elyanow,
- Paul Fields,
- Hussein Al-Asadi,
- Julia Greissl,
- Lance Baldo,
- Simona Semprini,
- Claudio Cerchione,
- Fabio Nicolini,
- Massimiliano Mazza,
- Ottavia M. Delmonte,
- Kerry Dobbs,
- Rocio Laguna-Goya,
- Gonzalo Carreño-Tarragona,
- Santiago Barrio,
- Luisa Imberti,
- Alessandra Sottini,
- Eugenia Quiros-Roldan,
- Camillo Rossi,
- Andrea Biondi,
- Laura Rachele Bettini,
- Mariella D’Angio,
- Paolo Bonfanti,
- Miranda F. Tompkins,
- Camille Alba,
- Clifton Dalgard,
- Vittorio Sambri,
- Giovanni Martinelli,
- Jason D. Goldman,
- Jason D. Goldman,
- James R. Heath,
- Helen C. Su,
- Luigi D. Notarangelo,
- Estela Paz-Artal,
- Joaquin Martinez-Lopez,
- Bryan Howie,
- Jonathan M. Carlson,
- Harlan S. Robins
Affiliations
- Thomas M. Snyder
- Adaptive Biotechnologies, Seattle, WA, United States
- Rachel M. Gittelman
- Adaptive Biotechnologies, Seattle, WA, United States
- Mark Klinger
- Adaptive Biotechnologies, Seattle, WA, United States
- Damon H. May
- Adaptive Biotechnologies, Seattle, WA, United States
- Edward J. Osborne
- Adaptive Biotechnologies, Seattle, WA, United States
- Ruth Taniguchi
- Adaptive Biotechnologies, Seattle, WA, United States
- H. Jabran Zahid
- Microsoft Research, Redmond, WA, United States
- Ian M. Kaplan
- Adaptive Biotechnologies, Seattle, WA, United States
- Jennifer N. Dines
- Adaptive Biotechnologies, Seattle, WA, United States
- Matthew T. Noakes
- Adaptive Biotechnologies, Seattle, WA, United States
- Ravi Pandya
- Microsoft Research, Redmond, WA, United States
- Xiaoyu Chen
- Adaptive Biotechnologies, Seattle, WA, United States
- Summer Elasady
- Adaptive Biotechnologies, Seattle, WA, United States
- Emily Svejnoha
- Adaptive Biotechnologies, Seattle, WA, United States
- Peter Ebert
- Adaptive Biotechnologies, Seattle, WA, United States
- Mitchell W. Pesesky
- Adaptive Biotechnologies, Seattle, WA, United States
- Patricia De Almeida
- Adaptive Biotechnologies, Seattle, WA, United States
- Hope O’Donnell
- Adaptive Biotechnologies, Seattle, WA, United States
- Quinn DeGottardi
- Adaptive Biotechnologies, Seattle, WA, United States
- Gladys Keitany
- Adaptive Biotechnologies, Seattle, WA, United States
- Jennifer Lu
- Adaptive Biotechnologies, Seattle, WA, United States
- Allen Vong
- Adaptive Biotechnologies, Seattle, WA, United States
- Rebecca Elyanow
- Adaptive Biotechnologies, Seattle, WA, United States
- Paul Fields
- Adaptive Biotechnologies, Seattle, WA, United States
- Hussein Al-Asadi
- Adaptive Biotechnologies, Seattle, WA, United States
- Julia Greissl
- Microsoft Research, Redmond, WA, United States
- Lance Baldo
- Adaptive Biotechnologies, Seattle, WA, United States
- Simona Semprini
- Unit of Microbiology - The Great Romagna Hub Laboratory, Pievesestina ITALY and DIMES, University of Bologna, Bologna, Italy
- Claudio Cerchione
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
- Fabio Nicolini
- Immunotherapy, Cell Therapy and Biobank (ITCB), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
- Massimiliano Mazza
- Immunotherapy, Cell Therapy and Biobank (ITCB), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
- Ottavia M. Delmonte
- Immune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
- Kerry Dobbs
- Immune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
- Rocio Laguna-Goya
- Department of Immunology, Hospital 12 de Octubre, CNIO, Complutense University, Madrid, Spain
- Gonzalo Carreño-Tarragona
- Hematology Department, Hospital 12 de Octubre, CNIO, Complutense University, Madrid, Spain
- Santiago Barrio
- Hematology Department, Hospital 12 de Octubre, CNIO, Complutense University, Madrid, Spain
- Luisa Imberti
- Laboratorio CREA, Department of Infectious and Tropical Diseases, and Medical Officer, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy
- Alessandra Sottini
- Laboratorio CREA, Department of Infectious and Tropical Diseases, and Medical Officer, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy
- Eugenia Quiros-Roldan
- Laboratorio CREA, Department of Infectious and Tropical Diseases, and Medical Officer, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy
- Camillo Rossi
- Laboratorio CREA, Department of Infectious and Tropical Diseases, and Medical Officer, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy
- Andrea Biondi
- 0Department of Pediatrics and Centro Tettamanti-European Reference Network PaedCan, EuroBloodNet, MetabERN-University of Milano-Bicocca-Fondazione MBBM-Ospedale San Gerardo, Monza, Italy
- Laura Rachele Bettini
- 0Department of Pediatrics and Centro Tettamanti-European Reference Network PaedCan, EuroBloodNet, MetabERN-University of Milano-Bicocca-Fondazione MBBM-Ospedale San Gerardo, Monza, Italy
- Mariella D’Angio
- 0Department of Pediatrics and Centro Tettamanti-European Reference Network PaedCan, EuroBloodNet, MetabERN-University of Milano-Bicocca-Fondazione MBBM-Ospedale San Gerardo, Monza, Italy
- Paolo Bonfanti
- 1Department of Infectious Diseases, University of Milano-Bicocca-Ospedale San Gerardo, Monza, Italy
- Miranda F. Tompkins
- 2The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
- Camille Alba
- 2The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
- Clifton Dalgard
- 3Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
- Vittorio Sambri
- Unit of Microbiology - The Great Romagna Hub Laboratory, Pievesestina ITALY and DIMES, University of Bologna, Bologna, Italy
- Giovanni Martinelli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
- Jason D. Goldman
- 4Swedish Medical Center, Seattle, WA, United States
- Jason D. Goldman
- 5Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, United States
- James R. Heath
- 6Institute for Systems Biology, Seattle, WA, United States
- Helen C. Su
- Immune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
- Luigi D. Notarangelo
- Immune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
- Estela Paz-Artal
- Department of Immunology, Hospital 12 de Octubre, CNIO, Complutense University, Madrid, Spain
- Joaquin Martinez-Lopez
- Hematology Department, Hospital 12 de Octubre, CNIO, Complutense University, Madrid, Spain
- Bryan Howie
- Adaptive Biotechnologies, Seattle, WA, United States
- Jonathan M. Carlson
- Microsoft Research, Redmond, WA, United States
- Harlan S. Robins
- Adaptive Biotechnologies, Seattle, WA, United States
- DOI
- https://doi.org/10.3389/fimmu.2024.1488860
- Journal volume & issue
-
Vol. 15
Abstract
IntroductionT cells are involved in the early identification and clearance of viral infections and also support the development of antibodies by B cells. This central role for T cells makes them a desirable target for assessing the immune response to SARS-CoV-2 infection.MethodsHere, we combined two high-throughput immune profiling methods to create a quantitative picture of the T-cell response to SARS-CoV-2. First, at the individual level, we deeply characterized 3 acutely infected and 58 recovered COVID-19 subjects by experimentally mapping their CD8 T-cell response through antigen stimulation to 545 Human Leukocyte Antigen (HLA) class I presented viral peptides. Then, at the population level, we performed T-cell repertoire sequencing on 1,815 samples (from 1,521 COVID-19 subjects) as well as 3,500 controls to identify shared “public” T-cell receptors (TCRs) associated with SARS-CoV-2 infection from both CD8 and CD4 T cells.ResultsCollectively, our data reveal that CD8 T-cell responses are often driven by a few immunodominant, HLA-restricted epitopes. As expected, the T-cell response to SARS-CoV-2 peaks about one to two weeks after infection and is detectable for at least several months after recovery. As an application of these data, we trained a classifier to diagnose SARS-CoV-2 infection based solely on TCR sequencing from blood samples, and observed, at 99.8% specificity, high early sensitivity soon after diagnosis (Day 3–7 = 85.1% [95% CI = 79.9–89.7]; Day 8–14 = 94.8% [90.7–98.4]) as well as lasting sensitivity after recovery (Day 29+/convalescent = 95.4% [92.1–98.3]).DiscussionThe approaches described in this work provide detailed insights into the adaptive immune response to SARS-CoV-2 infection, and they have potential applications in clinical diagnostics, vaccine development, and monitoring.
Keywords